diff --git a/dc/council/periods/22/acts/22-454.xml b/dc/council/periods/22/acts/22-454.xml
index eff2c469fd..8c6eb46e2f 100644
--- a/dc/council/periods/22/acts/22-454.xml
+++ b/dc/council/periods/22/acts/22-454.xml
@@ -7,12 +7,12 @@
To amend the Historic Landmark and Historic District Protection Act of 1978 to provide that grants available to assist homeowners with the rehabilitation of historic property under the Targeted Homeowner Grant Program may be used to rehabilitate a structure that contributes to the character of the Emerald Street Historic District, bounded by F Street, N.E, 13th Street, N.E., E Street, N.E., and 14th Street, N.E., in Ward 6; the Kingman Park Historic District, bounded by East Capitol Street, N.E., 19th Street, N.E., Maryland Avenue, N.E., M Street, N.E., and the Anacostia River, in Ward 7; and the Wardman Flats Historic Landmark, located within Square 519, bounded by 3rd Street, N.W., R Street, N.W., 4th Street, N.W., and Florida Avenue, N.W., in Ward 5.
2017-09-18
- 2018-11-07
+ 2018-12-15
D.C. Act 22-454
D.C. Law 22-19
- 0 DCR 0
+ 65 DCR 11198
diff --git a/dc/council/periods/22/acts/22-456.xml b/dc/council/periods/22/acts/22-456.xml
index 895037c6af..af9ec938ab 100644
--- a/dc/council/periods/22/acts/22-456.xml
+++ b/dc/council/periods/22/acts/22-456.xml
@@ -6,10 +6,10 @@
To amend the Confirmation Act of 1978 to clarify that the nomination of a member of the Housing Production Trust Fund Board shall be deemed disapproved if the Council does not approve the nomination within a 90-day period of review.
2018-01-08
- 2018-11-07
+ 2018-12-15
D.C. Act 22-456
- 0 DCR 0
+ 65 DCR 11202
@@ -26,7 +26,7 @@
(a)
Paragraph (33) is amended by striking the phrase "; and" and inserting a semicolon in its place.
-
+
(b)
diff --git a/dc/council/periods/22/acts/22-463.xml b/dc/council/periods/22/acts/22-463.xml
new file mode 100644
index 0000000000..eb35cd6f6b
--- /dev/null
+++ b/dc/council/periods/22/acts/22-463.xml
@@ -0,0 +1,281 @@
+
+
+ 22-896
+ 22-463
+ Eviction Procedure Reform Temporary Amendment Act of 2018
+ To amend, on a temporary basis, the Rental Housing Act of 1985 to prohibit the execution of residential evictions during precipitation, to establish the eviction procedure and requirements that a housing provider shall meet before, during, and immediately after a residential eviction, and to establish standards for the handling of an evicted tenant's personal property; and to clarify, in an eviction not subject to the Rental Housing Act of 1985, the legal status of an evicted tenant's remaining personal property and a landlord's civil liability for such property.
+
+ 2018-07-10
+ 2018-12-15
+
+
+ D.C. Act 22-463
+ 65 DCR 11372
+
+
+
+
+ 2018-10-10
+
+ Retained by the Council
+
+
+ BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Eviction Procedure Reform Temporary Amendment Act of 2018".
+
+ 2
+ The Rental Housing Act of 1985, effective July 17, 1985 (D.C. Law 6-10; D.C. Official Code § 42-3501.01 et seq.), is amended as follows:
+
+ (a)
+ Section 501(k) (D.C. Official Code § 42-3505.01(k)) is amended as follows:
+
+ (1)
+ Strike the phrase "tenant on any day when the National Weather Service predicts at 8:00 a.m. that the temperature at the National Airport weather station will fall below 32 degrees fahrenheit or 0 degrees centigrade within the next 24 hours." and insert the phrase "tenant:" in its place.
+
+
+ (2)
+ New paragraphs (1) and (2) are added to read as follows:
+
+
+ (1)
+ On any day when the National Weather Service predicts at 8:00 a.m. that the temperature at the National Airport weather station will fall below 32 degrees Fahrenheit or 0 degrees centigrade; or
+
+
+ (2)
+ When precipitation is falling at the location of the rental unit.
+
+
+ .
+
+
+
+
+ (b)
+ A new section 501a is added to read as follows:
+
+
+ 501a
+ Storage and disposal of tenants' personal property upon eviction.
+
+ (a)
+ A housing provider shall not remove an evicted tenant's personal property from a rental unit except as provided in this section.
+
+
+ (b)
+
+ (1)
+ In addition to any notification from the United States Marshals Service ("Marshals") to the tenant of the date of eviction, a housing provider shall deliver to the tenant a notice confirming the date of eviction not fewer than 14 days before the date of eviction by using the following methods:
+
+ (A)
+ Telephone or electronic communication, including by email or mobile text message;
+
+
+ (B)
+ First-class mail to the address of the rental unit; and
+
+
+ (C)
+ Conspicuous posting at the tenant's rental unit in a manner reasonably calculated to provide notice.
+
+
+
+ (2)
+ The notice shall:
+
+ (A)
+ State the tenant's name and the address of the rental unit;
+
+
+ (B)
+ Specify the date on which the eviction is scheduled to be executed;
+
+
+ (C)
+ State that the eviction will be executed on that date unless the tenant vacates the rental unit and returns control of the rental unit to the housing provider;
+
+
+ (D)
+ Prominently warn the tenant that any personal property left in the rental unit will be deemed abandoned 7 days after the time of eviction, excluding Sundays and federal holidays;
+
+
+ (E)
+ Include the phone numbers of the U.S. Marshals Service, Office of the Chief Tenant Advocate, and the District of Columbia Landlord Tenant Court; and
+
+
+ (F)
+ State that it is the final notice from the housing provider before the time of eviction, even if the eviction date is postponed by the court or Marshals;
+
+
+
+
+ (c)
+
+ (1)
+ At the time of eviction, the housing provider shall change the locks on the rental unit in the presence of the Marshals, at the housing provider's expense, and take legal possession of the rental unit by receipt of a document from the Marshals.
+
+
+ (2)
+ Any right of the evicted tenant to redeem the tenancy shall be extinguished at the time of eviction.
+
+
+
+ (d)
+
+ (1)
+ At the time of eviction, the housing provider shall send by first-class mail to the address of an emergency contact, if provided, and conspicuously post in a manner reasonably calculated to provide notice to the evicted tenant a notice containing the following information:
+
+ (A)
+ The name and phone number of at least one housing provider representative whom the tenant may contact and who can grant access to the rental unit on the housing provider's behalf pursuant to this subsection;
+
+
+ (B)
+ The phone number of the Office of the Chief Tenant Advocate;
+
+
+ (C)
+ The phone number of the United States Marshals Service;
+
+
+ (D)
+ The phone number of the District of Columbia Landlord Tenant Court; and
+
+
+ (E)
+ The text of this subsection attached to, or made a part of, the notice.
+
+
+
+ (2)
+ Any personal property of the evicted tenant present in the rental unit at the time of eviction shall remain in the rental unit for 7 days after the time of eviction, excluding Sundays and federal holidays, unless removed by the evicted tenant pursuant to this subsection.
+
+
+ (3)
+ The housing provider shall maintain and exercise reasonable care in the storage of the personal property of the evicted tenant during the period that the property remains in the rental unit pursuant to this subsection.
+
+
+ (4)
+
+ (A)
+ The housing provider shall grant the evicted tenant access to the rental unit to remove the evicted tenant's personal property during the period that the property remains in the rental unit pursuant to this subsection. Access shall be for no fewer than 8 continuous hours at times agreed to by the parties, without requiring payment of rent or service fees.
+
+
+ (B)
+ If the housing provider fails to grant access to the evicted tenant to remove the evicted tenant's personal property as provided in this paragraph, the evicted tenant shall have a right to injunctive relief, including requiring the housing provider to grant access to the evicted tenant at certain dates and times to retrieve the evicted tenant's personal property and extending the period during which the housing provider must store the evicted tenant's personal property.
+
+
+
+ (5)
+ Any of the evicted tenant's personal property remaining in the rental unit upon expiration of the period that the property remains in the rental unit pursuant to this subsection shall be deemed abandoned property.
+
+
+ (6)
+ The housing provider shall remove, or dispose of, any abandoned property in the rental unit upon the expiration of the period that the property remains in the rental unit pursuant to this subsection without any further notice or any other obligation to the evicted tenant.
+
+
+ (7)
+
+ (A)
+ The housing provider shall dispose of any abandoned property in any manner not prohibited by paragraph (8) of this subsection or otherwise expressly prohibited by law.
+
+
+ (B)
+ If the housing provider receives any funds from any sale of such abandoned property, the housing provider shall pay such funds to the account of the evicted tenant and apply any amounts due the housing provider by the evicted tenant, including the actual costs incurred by the housing provider in the eviction process described in this section.
+
+
+ (C)
+ If any funds are remaining after application, the remaining funds shall be treated as a security deposit under applicable law.
+
+
+
+ (8)
+ The housing provider is prohibited from placing or causing the placement of abandoned property in an outdoor space other than a lawful disposal receptacle; provided, that a housing provider may place abandoned property or cause abandoned property to be placed in an outdoor private or public space while in the process of transporting the property from the premises for disposal.
+
+
+ (9)
+ An evicted tenant is prohibited from disposing of or causing the disposal of personal property in an outdoor space other than a lawful disposal receptacle; provided, that an evicted tenant may place personal property or cause personal property to be placed in an outdoor private or public space while in the process of transporting the property from the premises.
+
+
+
+ (e)
+ The housing provider and anyone acting on behalf of the housing provider shall be immune from civil liability for loss or damage to the evicted tenant's abandoned property or claims related to its lawful disposal.
+
+
+ (f)
+ This section shall not apply to evictions carried out by the District of Columbia Housing Authority.
+
+
+ (g)
+ For the purposes of this section, the term "time of eviction" means the time at which the Marshals execute a writ of restitution.
+
+
+
+ .
+
+
+
+
+ 3
+ Other evictions.
+
+ (a)
+ At the time of an eviction not subject to the Rental Housing Act of 1985, effective July 17, 1985 (D.C. Law 6-10; D.C. Official Code § 42-3501.01 et seq.), the landlord shall change the locks on the leased premises in the presence of the United States Marshals Service ("Marshals"), at the landlord's expense, and take legal possession of the leased premises by receipt of a document from the Marshals.
+
+
+ (b)
+ Any right of the evicted tenant to redeem the tenancy shall be extinguished at the time of eviction.
+
+
+ (c)
+ Any personal property remaining in or about the leased premises at the time of eviction is deemed abandoned property.
+
+
+ (d)
+
+ (1)
+ The landlord shall dispose of any abandoned property in any manner not prohibited by subsection (e) of this section or otherwise expressly prohibited by law.
+
+
+ (2)
+ If the landlord receives any funds from any sale of such abandoned property, the landlord shall pay such funds to the account of the evicted tenant and apply any amounts due the landlord by the evicted tenant, including the actual costs incurred by the landlord in the eviction process described in this section.
+
+
+ (3)
+ If any funds are remaining after application, the remaining funds shall be treated as a security deposit under applicable law.
+
+
+
+ (e)
+ The landlord is prohibited from placing or causing the placement of abandoned property in an outdoor space other than a licensed disposal facility or lawful disposal receptacle; provided, that a landlord may place abandoned property or cause abandoned property to be placed in an outdoor private or public space while in the process of transporting the abandoned property from the leased premises for disposal.
+
+
+ (f)
+ The landlord and anyone acting on behalf of the landlord shall be immune from civil liability for loss or damage to the evicted tenant's abandoned property or claims related to its lawful disposal.
+
+
+ (g)
+ For the purposes of this section, the term "time of eviction" means the time at which the Marshals execute a writ of restitution.
+
+
+
+
+ 4
+ Repealer.
+ The Eviction Reform Emergency Amendment Act of 2018, effective July 24, 2018 (D.C. Act 22-425; 65 DCR 7709), is repealed.
+
+
+ 5
+ Fiscal impact statement.
+ The Council adopts the fiscal impact statement of the Budget Director as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).
+
+
+ 6
+ Effective date.
+
+ (a)
+ This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.
+
+
+ (b)
+ This act shall expire after 225 days of its having taken effect.
+
+
+
diff --git a/dc/council/periods/22/acts/22-464.xml b/dc/council/periods/22/acts/22-464.xml
new file mode 100644
index 0000000000..6fd25a9d0c
--- /dev/null
+++ b/dc/council/periods/22/acts/22-464.xml
@@ -0,0 +1,1867 @@
+
+
+ 22-626
+ 22-464
+ Revised Synthetics Abatement and Full Enforcement Drug Control Emergency Amendment Act of 2018
+ To amend, on an emergency basis, the District of Columbia Uniform Controlled Substances Act of 1981 to add certain classes and substances to the list of Schedule I controlled substances.
+
+ 2017-12-11
+ 2018-10-05
+
+ D.C. Act 22-464
+ 65 DCR 11377
+
+
+
+
+ 2018-10-05
+
+ Retained by the Council
+
+
+ BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Revised Synthetics Abatement and Full Enforcement Drug Control Emergency Amendment Act of 2018".
+
+ 2
+ The District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-901.01 et seq.), is amended as follows:
+
+ (a)
+ Section 102(27) (D.C. Official Code § 48-901.02(27)) is amended as follows:
+
+ (1)
+ Strike the phrase "as used in section 204(3) and section 206(1)(D)" and insert the phrase "as used in section 204(3), (5), and (6) and section 206(1)(D)" in its place.
+
+
+ (2)
+ Strike the phrase "As used in section 204(3)" and insert the phrase "As used in section 204(3), (5), and (6)" in its place.
+
+
+
+
+ (b)
+ Section 204 (D.C. Official Code § 48-902.04) is amended as follows:
+
+ (1)
+ Paragraph (3) is amended as follows:
+
+ (A)
+ The lead-in language is amended by striking the phrase "(for purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers):" and inserting a colon in its place.
+
+
+ (B)
+ New subparagraphs (G-i) through (G-xii) are added to read as follows:
+
+
+ (G-i)
+ 25I-NBOMe (also known as 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);
+
+
+ (G-ii)
+ 25B-NBOMe (also known as 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);
+
+
+ (G-iii)
+ 25C-NBOMe (also known as 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);
+
+
+ (G-iv)
+ 5-APB (also known as 1-(benzofuran-5-yl)propan-2-amine);
+
+
+ (G-v)
+ 5-APDB (also known as 1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine);
+
+
+ (G-vi)
+ 6-APB (also known as 1-(1-benzofuran-6-yl)propan-2-amine);
+
+
+ (G-vii)
+ 6-APDB (also known as1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine);
+
+
+ (G-viii)
+ 3-methoxy-PCE (also known as N-ethyl-1-(3-methoxyphenyl)cyclohexanamine);
+
+
+ (G-ix)
+ 3-methoxy-PCP (also known as 1-[1-(3-methoxyphenyl)cyclohexyl]piperidine);
+
+
+ (G-x)
+ 4-methoxy-PCP (also known as 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine);
+
+
+ (G-xi)
+ 5-MeO-DALT (also known as N,N-diallyl-5-methoxytryptamine);
+
+
+ (G-xii)
+ 4-AcO-DMT (also known as 5-acetoxy-N,N-dimethyltryptamine);
+
+
+ .
+
+
+ (C)
+ A new subparagraph (M-i) is added to read as follows:
+
+
+ (M-i)
+ Methoxetamine (also known as 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone);
+
+
+ .
+
+
+ (D)
+ Subparagraph (JJ) is amended by striking the phrase "; and" and inserting a semicolon in its place.
+
+
+ (E)
+ Subparagraph (KK) is amended by striking the semicolon and inserting the phrase "; and" in its place.
+
+
+ (F)
+ A new subparagraph (LL) is added to read as follows:
+
+
+ (LL)
+ Cathinone;
+
+
+ .
+
+
+
+ (2)
+ Paragraph (5) is amended to read as follows:
+
+
+ (5)
+ As used in this paragraph, the term "synthetic cathinones" includes any material, compound, mixture, or preparation that is not otherwise listed as a controlled substance in this schedule or in Schedules II through V, is not approved by the Food and Drug Administration as a drug, and is structurally derived from or contains any quantity of the following substances, their salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:
+
+ (A)
+ Classified Synthetic Cathinones:
+
+ (i)
+ Cathinones. Any compound, other than methylnenedioxy cathinones and pyrrolidine cathinones, containing a 2-amino-1-propanone structure with substitution at the 1-position with a monocyclic ring system, with or without alkyl, alkoxyl, or halo substitutions, and a substitution at the nitrogen atom by an alkyl group, cycloalkyl group, or incorporation into a heterocyclic structure. Examples of this structural class include:
+
+ (I)
+ Mephedrone, also known as:
+
+ (aa)
+ 2-(methylamino )-1-(4-methylphenyl)-1-propanone;
+
+
+ (bb)
+ 4-MeMC;
+
+
+ (cc)
+ 4-Methylmethcathinone;
+
+
+ (dd)
+ 4-Methylephedrone; or
+
+
+ (ee)
+ 4-MMC;
+
+
+
+ (II)
+ Dimethylcathinone, also known as:
+
+ (aa)
+ 2-(dimethylamino)-1-phenyl-1-propanone; or
+
+
+ (bb)
+ N,N-Dimethylcathinone;
+
+
+
+ (III)
+ Ethcathinone, also known as:
+
+ (aa)
+ 2-(ethylamino)-1-phenyl-1-propanone;
+
+
+ (bb)
+ Ethylcathinone;
+
+
+ (cc)
+ N-Ethylcathinone; or
+
+
+ (dd)
+ 2-Ethylaminobuphedro;
+
+
+
+ (IV)
+ Buphedrone, also known as:
+
+ (aa)
+ 2-(methylamino)-1-phenylbutan-l-one; or
+
+
+ (bb)
+ MABP;
+
+
+
+ (V)
+ 3,4-DMMC, also known as:
+
+ (aa)
+ 1-(3,4-dimethylphenyl)-2-(methylamino)-1- propanone; or
+
+
+ (bb)
+ 3,4-Dimethylmethcathinone;
+
+
+
+ (VI)
+ EMC, also known as:
+
+ (aa)
+ 1-{4-ethylphenyl)-2-(methylamino)propan-1-one;
+
+
+ (bb)
+ 4-EMC; or
+
+
+ (cc)
+ 4-Ethylmethcathinone;
+
+
+
+ (VII)
+ Fluoromethcathinone (also known as 1-(4-fluorophenyl)-2-(methylamino) propan-1-one);
+
+
+ (VIII)
+ 3-FMC, also known as (:
+
+ (aa)
+ 3-fluoro-N-methylcathinone); or
+
+
+ (bb)
+ 1-(3-fluorophenyl)-2-(methylamino)propan-1- one;
+
+
+
+ (IX)
+ 4-FMC, also known as:
+
+ (aa)
+ 1-(4-fluorophenyl)-2-(methylamino)propan-1-one;
+
+
+ (bb)
+ 4-fluoro-N-methylcathinone; or
+
+
+ (cc)
+ Flephedrone;
+
+
+
+ (X)
+ 4-MeBP, also known as:
+
+ (aa)
+ 2-(methylamino)-1-(4-methylphenyl)-1-butanone;
+
+
+ (bb)
+ 4-Methylbuphedrone;
+
+
+ (cc)
+ 4-methyl BP; or
+
+
+ (dd)
+ 4-MeMABP;
+
+
+
+ (XI)
+ 3-MEC, also known as:
+
+ (aa)
+ 2-(ethylamino )-1-(m-tolyl)propan-l-one; or
+
+
+ (bb)
+ 3-Methyl-N-ethylcathinone;
+
+
+
+ (XII)
+ 4-MEC, also known as:
+
+ (aa)
+ 2-(ethylamino)-1-(4-methylphenyl)-1-propanone; or
+
+
+ (bb)
+ 4-Methyl-N-ethylcathinone;
+
+
+
+ (XIII)
+ 3-MMC, also known as:
+
+ (aa)
+ 2-(methylamino)-1-(3-methylphenyl)-1-propanone;
+
+
+ (bb)
+ 3-methyl MS; or
+
+
+ (cc)
+ 3-Methylmethcathinone;
+
+
+
+ (XIV)
+ Methedrone (also known as l-(4-methoxyphenyl)-2-(methylamino)-1-propanone); and
+
+
+ (XV)
+ Pentedrone (also known as 2-(methylamino)-1-phenylpentan-1-one);
+
+
+
+ (ii)
+ Methylenedioxy Cathinones. Any compound containing a 2- amino-1-propanone structure with substitution at the 1-position with a monocyclic or fused polycyclic ring system and a substitution at any position of the ring system with an alkyl, haloalkyl, halogen, alkylenedioxy, or alkoxy group, whether or not further substituted at any position on the ring system to any extent. Examples of this structural class include:
+
+ (I)
+ 3-fluoromethylone;
+
+
+ (II)
+ Methylone, also known as
+
+ (aa)
+ 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-propanone; or
+
+
+ (bb)
+ 3,4-Methylenedioxy-N-methylcathinone);
+
+
+
+ (III)
+ N-ethyl Pentylone, also known as:
+
+ (aa)
+ Ephylone; or
+
+
+ (bb)
+ 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone;
+
+
+
+ (IV)
+ bk-MDDMA, also known as:
+
+ (aa)
+ 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one;
+
+
+ (bb)
+ Dimethylone;
+
+
+ (cc)
+
+ N,N-dimethyl-3',4'-methylenedioxycathinone;
+
+
+ (dd)
+
+ N,N-dimethyl-3,4-methylenedioxycathinone; or
+
+
+ (ee)
+ N,N-Dimethyl MDCATH;
+
+
+
+ (V)
+ Butylone, also known as 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one); and
+
+
+ (VI)
+ Ethylone, also known as:
+
+ (aa)
+ 3,4-Methylenedioxy-N-ethylcathinone; or
+
+
+ (bb)
+ MDEC;
+
+
+
+
+ (iii)
+ Pyrrolidine Cathinones. Any compound containing a 2-amino-1-propanone structure with substitution at the 1-position with an alkyl, cyclic, or fused polycyclic ring system and a substitution at the 3-position carbon with an alkyl, haloalkyl, halogen, alkoxy or alkylenedioxy group, and a substitution at the nitrogen atom incorporation into a heterocyclic structure, with or without further halogen substitutions. Examples include:
+
+ (I)
+ α-PVP (also known as α-pyrrolidinopentiophenone);
+
+
+ (II)
+ α-pyrrolidinopropiophenone, also known as:
+
+ (aa)
+ l-phenyl-2-(1-pyrrolidinyl)-l-propanone; or
+
+
+ (bb)
+ α-PPP;
+
+
+
+ (III)
+ α-PBP, also known as:
+
+ (aa)
+ 1-phenyl-2-(1-pyrrolidinyl)-1-butanone; or
+
+
+ (bb)
+ α-pyrrolidinobutiophenone;
+
+
+
+ (IV)
+ MDPBP, also known as:
+
+ (aa)
+ 1-(l ,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-butanone;
+
+
+ (bb)
+ 3,4-Methylenedioxy-α-Pyrrolidinobutiophenone; or
+
+
+ (cc)
+ 3,4-MDPBP;
+
+
+
+ (V)
+ MDPPP, also known as:
+
+ (aa)
+ 1-(l,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-propanone; or
+
+
+ (bb)
+ 3,4-Methylenedioxy-α-Pyrrolidinopropiophenone;
+
+
+
+ (VI)
+ MDPV, also known as:
+
+ (aa)
+ 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone; or
+
+
+ (bb)
+ 3,4-Methylenedioxy Pyrovalerone;
+
+
+
+ (VII)
+ 4-MePPP, also known as
+
+ (aa)
+ 4'-methyl-α-Pyrrolidinopropiophenone;
+
+
+ (bb)
+ 4'-methyl PPP; or
+
+
+ (cc)
+ 2-(pyrrolidin-l-yl)-1-(p-tolyl)propan-l-one;
+
+
+
+ (VIII)
+ 4'-methyl PHP, also known as:
+
+ (aa)
+ 4'-methyl-α-pyrrolidinohexanophenone;
+
+
+ (bb)
+ MPHP;
+
+
+ (cc)
+ 4'-methyl-α-PHP; or
+
+
+ (dd)
+ PV4;
+
+
+
+ (IX)
+ Naphyrone, also known as:
+
+ (aa)
+ (RS)-1-naphthalen-2-yl-2-pyrrolidin-l- ylpentan-1-one; or
+
+
+ (bb)
+ Naphpyrovalerone; and
+
+
+
+ (X)
+ C-PVP, also known as:
+
+ (aa)
+ 4-Chloro-α-PVP; or
+
+
+ (bb)
+ 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan- 1-one; or
+
+
+
+
+ (iv)
+ Piperazine Stimulants. Any compound containing or structurally derived from a piperazine, or diethylenediamine, structure with or without substitution at one of the nitrogen atoms of the piperazine ring to any extent, including alkyl, cycloalkyl, or fused ring systems, with or without further halogen substitutions. Examples include:
+
+ (I)
+ BZP, also known as:
+
+ (aa)
+ 1-(phenylmethyl)-piperazine;
+
+
+ (bb)
+ 1-Benzylpiperazine; or
+
+
+ (cc)
+ N-Benzylpiperazine; and
+
+
+
+ (II)
+ TMFPP, also known as:
+
+ (aa)
+ 1-[3-(trifluoromethyl)phenyl]-piperazine;
+
+
+ (bb)
+ 1-(m-Trifluoromethylphenyl) piperazine; or
+
+
+ (cc)
+ 3-Trifluoromethylphenylpiperazine.
+
+
+
+
+
+ (B)
+ Unclassified Synthetic Cathinones:
+
+ (i)
+ Aminorex (also known as (RS)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine);
+
+
+ (ii)
+ -ET, also known as:
+
+ (I)
+ -ethyl-1H-indole-3-ethanamine;
+
+
+ (II)
+ -ethyltryptamine; or
+
+
+ (III)
+ 3-Indolybutylamine;
+
+
+
+ (iii)
+ -MT, also known as:
+
+ (I)
+ -methyl-1H-indole-3-ethanamine; or
+
+
+ (II)
+ -methyltryptamine;
+
+
+
+ (iv)
+ EMA, also known as:
+
+ (I)
+ N-ethyl-α-methyl-benzeneethanamine; or
+
+
+ (II)
+ N-Ethylamphetamine;
+
+
+
+ (v)
+ Fenethylline (also known as (RS)-1,3-dimethyl-7-[2-(1- bpphenylpropan-2-ylamino)ethyl]purine-2,6-dione);
+
+
+ (vi)
+ N-hydroxy MDA, also known as:
+
+ (I)
+ MDOH;
+
+
+ (II)
+ N-hydroxy-α-methyl-1,3-benzodioxole-5-ethanamine; or
+
+
+ (III)
+ N-Hydroxy-3,4-methylenedioxyamphetamine; and
+
+
+
+ (vii)
+ N,N-DMA, also known as:
+
+ (I)
+ N,N,α-trimethyl-benzeethanamine;
+
+
+ (II)
+ N,N-Dimethylamphetamine;
+
+
+ (III)
+ Dimetamfetamine; or
+
+
+ (IV)
+ Metrotonin.
+
+
+
+
+
+ .
+
+
+ (b)
+ Section 204 (D.C. Official Code § 48-902.04) is amended as follows:
+
+ (3)
+ New paragraphs (6) and (7) are added to read as follows:
+
+
+ (6)
+ Synthetic cannabimimetic agents (also known as "synthetic cannabinoids"), which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:
+
+ (A)
+ Classified Synthetic Cannabimimetic Agents:
+
+ (i)
+ Adamantanoylindoles: Any compound containing or structurally derived from an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Examples include:
+
+ (I)
+ AB-001, also known as:
+
+ (aa)
+ (1s,3s)-adamantan-1-yl(1-pentyl-1H-indol-3-yl)methanone; or
+
+
+ (bb)
+ JWH 018 adamantyl analog; and
+
+
+
+ (II)
+ AM-1248, also known as:
+
+ (aa)
+ [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]tricyclo[3.3.1.13,7]dec-1-yl-methanone; or
+
+
+ (bb)
+ AM1248;
+
+
+
+
+ (ii)
+ Benzimidazole Ketone: Any compound containing or structurally derived from (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Benzimidazole Ketones include:
+
+ (I)
+ FUBIMINA, also known as:
+
+ (aa)
+ (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone; or
+
+
+ (bb)
+ AM2201 benzimidazole analog; and
+
+
+
+ (II)
+ JWH-018 benzimidazole analog, also known as:
+
+ (aa)
+ naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-yl)methanone; or
+
+
+ (bb)
+ BIM-018;
+
+
+
+
+ (iii)
+ Benzoylindoles: Any compound containing or structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples include:
+
+ (I)
+ AM-630, also known as:
+
+ (aa)
+ [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone;
+
+
+ (bb)
+ AM630; or
+
+
+ (cc)
+ Iodopravadoline ;
+
+
+
+ (II)
+ AM-661 (also known as 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole);
+
+
+ (III)
+ AM-679, also known as:
+
+ (aa)
+ (2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone; or
+
+
+ (bb)
+ AM679;
+
+
+
+ (IV)
+ AM-694, also known as:
+
+ (aa)
+ [1-(5-fluoropentyl)-1H-indol-3-yl](2-iodophenyl)-methanone;
+
+
+ (bb)
+ 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; or
+
+
+ (cc)
+ AM694;
+
+
+
+ (V)
+ AM-1241, also known as:
+
+ (aa)
+ (2-iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone; or
+
+
+ (bb)
+ AM1241;
+
+
+
+ (VI)
+ AM-2233, also known as:
+
+ (aa)
+ (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-methanone; or
+
+
+ (bb)
+ AM2233;
+
+
+
+ (VII)
+ RCS-4, also known as:
+
+ (aa)
+ (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone; or
+
+
+ (bb)
+ SR-19; and
+
+
+
+ (VIII)
+ WIN 48,098, also known as
+
+ (aa)
+ (4-methoxyphenyl)[2-methyl]-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-methanone; or
+
+
+ (bb)
+ "Pravadoline";
+
+
+
+
+ (iv)
+ Carbazole Ketone: Any compound containing or structurally derived from (9H-carbazole-3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples include EG-018 (also known as naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone);
+
+
+ (v)
+ lndazole Amide: Any compound containing or structurally derived from 3-carboxamide-lH-indazoles, whether or not substituted in the indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-lH-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen. Examples include:
+
+ (I)
+ AB-CHMINACA (also known as N-(1-amino-3-methyl-l-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);
+
+
+ (II)
+ AB-FUBINACA (also known as N-(1-amino-3-346 methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide);
+
+
+ (III)
+ AB-PINACA (also known as N-(l-amino-3-methyl-l-oxobutan-2-yl)-1-pentyl-IH-indazole-3-carboxamide);
+
+
+ (IV)
+ 5F AB-PINACA, also known as:
+
+ (aa)
+ N-(l-amino-3-methyl-1-oxobutan-2-yl)-l-(5-fluoropentyl)-1H-indazole-3-carboxamide); or
+
+
+ (bb)
+ 5-fluoro AB-PINACA;
+
+
+
+ (V)
+ ADB-FUBINACA (also known as N-(1-amino-3,3-dimethyl-l-oxobutan-2-yl)-1-(4-fluorobenzyl)-1-H-indazole-3-carboxamide);
+
+
+ (VI)
+ ADB-PINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-l-pentyl-1H-indazole-3-carboxamide);
+
+
+ (VII)
+ 5F ADB-PINACA, also known as:
+
+ (aa)
+ N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or
+
+
+ (bb)
+ 5-fluoro ADB-PINACA;
+
+
+
+ (VIII)
+ FUB-AMB, also known as:
+
+ (aa)
+ methyl (l-(4-fluorobenzyl)-IH-indazole-3-carbonyl)-L-valinate;
+
+
+ (bb)
+ AMB-FUBINACA; or
+
+
+ (cc)
+ MMB-FUBINACA;
+
+
+
+ (IX)
+ 5-fluoro-AMB (also known as (S)- methyl 2- (1-(5-fluoropentyl)-lH-indazole-3-carboxamido)-3-methylbutanoate);
+
+
+ (X)
+ MAB-CHMINACA (also known as N-(1-amino-3,3-dimethyl-l-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide );
+
+
+ (XI)
+ MMB CHMINACA, also known as:
+
+ (aa)
+ methyl (S)-2-(l-(cyclohexylmethyl)-IH-indole-3-carboxamido )-3,3-dimethylbutanoate; or
+
+
+ (bb)
+ MDMB-CHMICA;
+
+
+
+ (XII)
+ 5F MN-18, also known as:
+
+ (aa)
+ l-(5-fluoropentyl)-N-l-naphthalenyl-IH-indazole-3-carboxamide; or
+
+
+ (bb)
+ 5-fluoro MN-18;
+
+
+
+ (XIII)
+ 5F-APINACA, also known as:
+
+ (aa)
+ 5-fluoro-APINACA
+
+
+ (bb)
+ 5F-AKB-48;
+
+
+ (cc)
+ 5F-AKB48;
+
+
+ (dd)
+ N-((3s,5s,7s)-adamantan-l-yl)-l-(5-fluoropentyl)-1H-indazole-3-carboxamide; or
+
+
+ (ee)
+
+ N-(l-adamantyl)-1-(5-fluoropentyl)-lH-indazole-3-carboxamide); and
+
+
+
+ (XIV)
+ APINACA, also known as:
+
+ (aa)
+ AKB-48;
+
+
+ (bb)
+ AKB48;
+
+
+ (cc)
+ l-pentyl-N-tricyclo[3.3.l .13,7]dec-l-yl-1H-indazole-3-carboxamide; or
+
+
+ (dd)
+
+ N-(1-adamantyl)-1-pentyl-lH-indazole-3-carboxamide;
+
+
+
+
+ (vi)
+ Cyclohexylphenols: Any compound containing or structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent. Examples include:
+
+ (I)
+ CP 47,497 (also known as 2-[(1S,3R)-3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol);
+
+
+ (II)
+ CP 47,497 C8 homologue, also known as:
+
+ (aa)
+ rel-2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol; or
+
+
+ (bb)
+ Cannabicyclohexanol;
+
+
+
+ (III)
+ CP 55,490;
+
+
+ (IV)
+ CP 55,940 (also known as 5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol); and
+
+
+ (V)
+ CP 56,667;
+
+
+
+ (vii)
+ Cyclopropanoylindoles: Any compound containing or structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent. Cyclopropanoylindoles include cyclopropylmethanone indoles, as well as other cycloalkanemethanones, whether or not substituted at the nitrogen atom on the indole ring, whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cycloalkane ring to any extent. Examples of this structural class include:
+
+ (I)
+ A-796,260, also known as:
+
+ (aa)
+ [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or
+
+
+ (bb)
+ A-796260;
+
+
+
+ (II)
+ A-834,735, also known as:
+
+ (aa)
+ [1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or
+
+
+ (bb)
+ A-834735;
+
+
+
+ (III)
+ AB-034 (also known as [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone);
+
+
+ (IV)
+ UR-144 (also known as 1-pentyl-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole);
+
+
+ (V)
+ 5-bromo-UR-144, also known as:
+
+ (aa)
+ [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or
+
+
+ (bb)
+ UR-144 N-(5-bromopentyl) analog;
+
+
+
+ (VI)
+ 5-chloro-UR-144, also known as:
+
+ (aa)
+ 1-(5-chloropentyl)-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole; or
+
+
+ (bb)
+ 5Cl-UR-144;
+
+
+
+ (VII)
+ XLR11, also known as:
+
+ (aa)
+ 1-(5-fluoropentyl)-3-(2,2,3, 3-tetramethylcyclopropoyl)indole;
+
+
+ (bb)
+ 5-FUR-144; or
+
+
+ (cc)
+ 5-fluoro UR-144; and
+
+
+
+ (VIII)
+ FUB-144 (also known as [1-{4-Fluorobenzyl)-lH-indol-3-yl]{2,2,3 ,3-tetramethylcyclopropyl)methanone);
+
+
+
+ (viii)
+ Hexahydrodibenzopyrans: Any compound containing or structurally derived from Hexahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, except where contained in cannabis or cannabis resin;
+
+
+ (ix)
+ Indazole Ester (also known as Carboxylate indazole): Any compound containing or structurally derived from 3-carboxylate-indazoles, whether or not substituted in the indazole ring to any extent or substituted to any degree on the carboxylate, whether or not substituted to any extent in the indazole ring or on the carboxylate oxygen. Examples of indazole esters include 5-fluoro SDB-005, also known as:
+
+ (I)
+ naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate; or
+
+
+ (II)
+ 5F SDB-005;
+
+
+
+ (x)
+ Indole Amides: Any compound containing or structurally derived from or containing a 1H-Indole-3-carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole amides include:
+
+ (I)
+ Adamantylamidoindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide structure, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent;
+
+
+ (II)
+ Adamantylindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the adamantyl ring to any extent;
+
+
+ (III)
+ 5F ABICA, also known as:
+
+ (aa)
+ (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;
+
+
+ (bb)
+ N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; or
+
+
+ (cc)
+ 5-fluoro ABICA;
+
+
+
+ (IV)
+ ADBICA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide));
+
+
+ (V)
+ 5F-ADBICA, also known as:
+
+ (aa)
+ N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; or
+
+
+ (bb)
+ 5-fluoro-ADBICA;
+
+
+
+ (VI)
+ NNE1 (also known as N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
+
+
+ (VII)
+ 5F-NNE1, also known as:
+
+ (aa)
+ 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide); or
+
+
+ (bb)
+ 5-fluoro-NNE1;
+
+
+
+ (VIII)
+ SDB-006 (also known as N-benzyl-1-pentyl-1H- indole-3-carboxamide);
+
+
+ (IX)
+ 5F-SDB-006, also known as:
+
+ (aa)
+ N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide); or
+
+
+ (bb)
+ 5-fluoro-SDB-006;
+
+
+
+ (X)
+ 2NE 1, also known as:
+
+ (aa)
+ APICA;
+
+
+ (bb)
+ JWH 018 adamantyl carboxamide; or
+
+
+ (cc)
+ 1-pentyl-N-tricyclo[3.3. l .13, 7]dec-1-yl-1H-indole-3-carboxamide;
+
+
+
+ (XI)
+ STS-135, also known as:
+
+ (aa)
+ 1-(5-fluoropentyl)-N-tricyclo[3.3. l. l 3, 7]dec-1-yl-l H-indole-3-carboxamide;
+
+
+ (bb)
+ N-adamantyl-l-fluoropentylindole-3-Carboxamide;
+
+
+ (cc)
+ 5F-APICA; or
+
+
+ (dd)
+ 5-fluoro-APICA;
+
+
+
+ (XII)
+ SDB-006 (also known as N-benzyl-1-pentyl-lH-indole-3-carboxamide); and
+
+
+ (XIII)
+ 5-fluoro-MDMB-PICA (also known as N-[[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester);
+
+
+
+ (xi)
+ Indole Esters: Any compound containing or structurally derived from a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole esters may also be referred to as Quinolinylindolecarboxylates. Indole esters include:
+
+ (I)
+ Quinolinyl ester indoles, or any compound containing or structurally derived from Quinolinyl ester indoles, being any compound containing or structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl ester, whether or not substituted in the indole ring to any extent or the quinolone ring to any extent;
+
+
+ (II)
+ BB-22, also known as:
+
+ (aa)
+ 1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;
+
+
+ (bb)
+ quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate; or
+
+
+ (cc)
+ QUCHIC;
+
+
+
+ (III)
+ FDU-PB-22 (also known as naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
+
+
+ (IV)
+ FUB-PB-22, also known as:
+
+ (aa)
+ 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylic acid, 8-quinolinyl ester; or
+
+
+ (bb)
+ Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate;
+
+
+
+ (V)
+ NM2201, also known as:
+
+ (aa)
+ naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; or
+
+
+ (bb)
+ CBL-2201;
+
+
+
+ (VI)
+ PB-22, also known as:
+
+ (aa)
+ 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid;
+
+
+ (bb)
+ quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;
+
+
+ (cc)
+ 8-Quinolinyl 1-pentyl-1H-indole-3-carboxylate; or
+
+
+ (dd)
+ "QUPIC"; and
+
+
+
+ (VII)
+ 5F-PB-22, also known as:
+
+ (aa)
+ 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;
+
+
+ (bb)
+ quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;
+
+
+ (cc)
+ 8-Quinolinyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;
+
+
+ (dd)
+ 5-fluoro-PB-22; or
+
+
+ (ee)
+ 5-fluoro QUPIC;
+
+
+
+
+ (xii)
+ Naphthoylindoles: Any compound containing or structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including the following: AM-678, AM-1220, AM-1221, AM-1235, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55-212. Napthoylindoles also include:
+
+ (I)
+ AM-2201 (also known as (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); and
+
+
+ (II)
+ WIN 55,212-2, also known as:
+
+ (aa)
+ (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or
+
+
+ (bb)
+ [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone);
+
+
+
+
+ (xiii)
+ Naphthoylnaphthalenes: Any compound containing or structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent. Naphthoylnaphthalenes include CB-13 (also known as CRA-13 or 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone;
+
+
+ (xiv)
+ Naphthoylpyrroles: Any compound containing or structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392;
+
+
+ (xv)
+ Naphthylamidoindoles: Any compound containing or structurally derived from a N-(naphthyl)-indole-3-carboxamide structure, whether or not further substituted to any extent in the indole ring or in the naphthyl ring;
+
+
+ (xvi)
+ Naphthylmethyl Indoles: Any compound containing orstructurally derived from 1H-indol-3-yl-(1-naphthyl)methane structure, also known as napthylmethylindoles, with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2- (4-morpholinyl)ethyl group, or 1-(N-methyl-2-pyrrolidinyl)methyl, l-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent. Examples of this structural class include:
+
+ (I)
+ JWH-175 (also known as 3-(1-naphthalenylmethyl)-1-pentyl-1 H-indole );
+
+
+ (II)
+ JWH-184 (also known as 3-[(4-methyl-1-naphthalenyl)methyl)-1-pentyl-l H-indole);
+
+
+ (III)
+ JWH-185 (also known as 3-[(4-methoxy-1-naphthalenyl)methyl]-1 -pentyl-1 H-indole);
+
+
+ (IV)
+ JWH-192 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethane);
+
+
+ (V)
+ JWH-194 (also known as 2-methyl-1-pentyl-lH-indol-3-yl-( 4-methyl-1-naphthyl)methane);
+
+
+ (VI)
+ JWH-195 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethane);
+
+
+ (VII)
+ JWH-196 (also known as 2-methyl-3-(1-naphthalenylmethyl)-1-pentyl-lH-Indole);
+
+
+ (VIII)
+ JWH-197 (also known as 2-methyl-l-pentyl-lH-indol-3-yl-( 4-methoxy-1-naphthyl)methane); and
+
+
+ (IX)
+ JWH-199 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethane);
+
+
+
+ (xvii)
+ Naphthylmethylindenes: Any compound containing or structurally derived from a naphthylideneindene structure or that is structurally derived from 1-(1-naphthylmethylene)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-( 4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples include:
+
+ (I)
+ JWH-171;
+
+
+ (II)
+ JWH-176 (also known as 1-((E)-{3-pentyl-1 H-inden-1-ylidene)methyl]-naphthalene); and
+
+
+ (III)
+ JWH-220;
+
+
+
+ (xviii)
+ Phenylacetylindoles: Any compound containing or structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including: JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8, SR-18, and Cannabipiperidiethanone (also known as 2-(2-methoxyphenyl)-1-[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-ethanone);
+
+
+ (xix)
+ Quinolinoyl pyrazole: Any compound containing or structurally derived from Quinolinoyl pyrazole carboxylate (also known as Quinolinyl fluoropentyl fluorophenyl pyrazole carboxylate);
+
+
+ (xx)
+ Tetrahydrobenzochromen: Any compound containing or structurally derived from (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Includes tetrahydrodibenzopyrans, or any compound containing or structurally derived from tetrahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, but does not include tetrahydrodibenzopyrans that are contained in cannabis or cannabis resin. Examples of this structural class include:
+
+ (I)
+ AM-087 (also known as (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)- 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
+
+
+ (II)
+ AM-411 (also known as (6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
+
+
+ (III)
+ HU-210, also known as:
+
+ (aa)
+ 3-(1,1'-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;
+
+
+ (bb)
+ [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol;
+
+
+ (cc)
+ 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; or
+
+
+ (dd)
+ 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol;
+
+
+
+ (IV)
+ HU-211, also known as:
+
+ (aa)
+ 3-(1,1-dimethylheptyl)-6aS,7,10,10aS-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;
+
+
+ (bb)
+ (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
+
+
+ (cc)
+ (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or
+
+
+ (dd)
+ "Dexanabinol";
+
+
+
+ (V)
+ HU-243, also known as
+
+ (aa)
+ (6aR,8S,9S,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol; or
+
+
+ (bb)
+ 3-dimethylheptyl-11-hydroxyhexahydrocannabinol;
+
+
+
+ (VI)
+ JWH-051 (also known as (6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol);
+
+
+ (VII)
+ JWH-133 (also known as (6aR,10aR)-3-(1,1-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran); and
+
+
+ (VIII)
+ JWH-359 (also known as (6aR,10aR)- 1-methoxy-6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene);
+
+
+
+ (xxi)
+ Δ8 Tetrahydrocannabinol: Any compound containing or structurally derived from 11-hydroxy-Δ8-tetrahydrocannabinol structure, also known as dibenzopyrans, with further substitution on the 3-pentyl group by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkyethyl, 1-(n-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group;
+
+
+ (xxii)
+ Tetramethylcyclopropane-thiazole carboxamides: Any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2- (4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent, including the group Tetramethylcyclopropyl thiazoles, or any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- 2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent. Tetramethylcyclopropane-thiazole carboxamides also include A-836,339, also known as:
+
+ (I)
+ [N(Z)]-N-[3-(2-methoxyethyl)-4,5-dimethyl-2(3H)-thiazolylidene]-2,2,3,3-tetramethyl-cyclopropanecarboxamide;
+
+
+ (II)
+ N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropanecarboxamide: and
+
+
+ (III)
+ A-836339;
+
+
+
+ (xxiii)
+ Benzodihydropyrans: Any compound containing or structurally derived from benzodihydropyrans, by substitution on the benzyl ring by hydroxy, alkyl, haloalkyl, alkoxy, cycloalkyl, alkene, haloalkene, cycloalkane, or by substitution on the pyran ring by alkyl, cycloalkyl, cycloalkene, or cycloalkoxy group to any extent. Examples of this structural class include:
+
+ (I)
+ AM-855 (also known as (4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9, 10,11,12b-octahydronaphtho[3,2-c]isochromen-l 2-ol);
+
+
+ (II)
+ AM-905 (also known as (6aR,9R, l0aR)-3-[(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a, 7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol);
+
+
+ (III)
+ AM-906 (also known as (6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a, 7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol);
+
+
+ (IV)
+ AM-2389 (also known as (6aR,9R,10aR)-3-(l-hexylcyclobut-l-yl)-6a, 7,8,9, I 0, I Oa-hexahydro-6,6-dimethyl-6H-dibenzo[b,d)pyran-1,9 diol);and
+
+
+ (V)
+ JWH-057 (also known as (6aR,10aR)-3-(1,l-dimethylheptyl)-6a, 7, 10, 10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran); and
+
+
+
+ (xxiv)
+ Benzimidazole Ketone: Any compound containing or structurally derived from [IH-indazol-3-yl](l-naphthyl)methanone structure with or without substitution at either nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, l-(N-methyl-2-pyrrolidinyl)methyl, l-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, l-amino-3-methyl-1-oxobutan-2-yl, l-amino-3, 3-dimethyl-1-oxobutan-2-yl, l-methoxy-3-methyl-1-oxobutan-2-yl, l-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples of this structural class include:
+
+ (I)
+ THJ-2201 (also known as [l-(5-Fluoropentyl)-lH-indazol-3-yl](l-naphthyl)methanone); and
+
+
+ (II)
+ THJ-018 (also known as l-naphthalenyl(l-pentyl-IH-indazol-3-yl)-methanone);
+
+
+
+
+ (B)
+ Unclassified Synthetic Cannabimimetic Agents:
+
+ (i)
+ AM-356, also known as:
+
+ (I)
+ AM356;
+
+
+ (II)
+ arachidonyl-1'-hydroxy-2'-propylamide;
+
+
+ (III)
+ N-(2-hydroxy-1R-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide;
+
+
+ (IV)
+ (R)-(+)-Arachidonyl-1'-Hydroxy-2'-Propylamide;
+
+
+ (V)
+ Methanandamide; or
+
+
+ (VI)
+ R-1 Methanandamide;
+
+
+
+ (ii)
+ BAY38-7271 (also known as (-)-(R)-3-(2-Hydroxymethylindanyl -4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate);
+
+
+ (iii)
+ CP 50,556-1, also known as:
+
+ (I)
+ 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6, 6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate;
+
+
+ (II)
+ [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5- phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-; octahydrophenanthridin-1-yl] acetate;
+
+
+
+ (III)
+ [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; or
+
+ (IV)
+ "Levonantradol";
+
+
+
+ (iv)
+ HU-308 (also known as (91R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol);
+
+
+ (v)
+ HU-331 (also known as 3-hydroxy-2-[(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione);
+
+
+ (vi)
+ JTE-907 (also known as N-(benzol[1,3]dioxol-5-ylmethyl) –7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide);
+
+
+ (vii)
+ Mepirapim (also known as (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl) Methanone);
+
+
+ (viii)
+ URB597 (also known as [3-(3-carbamoylphenyl)phenyl] –N-Cyclohexylcarbamate);
+
+
+ (ix)
+ URB602, also known as:
+
+ (I)
+ [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; or
+
+
+ (II)
+ cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;
+
+
+
+ (x)
+ URB754 (also known as 6-methyl-2-[(4-methylphenyl)amino] -4H-3,1-benzoxazin-4-one); and
+
+
+ (xi)
+ URB937 (also known as 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl Cyclohexylcarbamate).
+
+
+
+
+ (7)
+ Synthetic opioids, which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:
+
+ (A)
+ Classified Synthetic Opioids:
+
+ (i)
+ Fentanyls: Any compound, other than carbomethoxyfentanyls, containing or structurally derived from N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide, whether or not substituted on the methanone group with an alkyl, alkene, halo, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, cyanoalkyl, hydroxyalkyl, furanyl, or alkoxy, and whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Examples of fentanyls include:
+
+ (I)
+ Fentanyl (also known as N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide);
+
+
+ (II)
+ Furanylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide);
+
+
+ (III)
+ Acetylfentanyl (also known as N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide);
+
+
+ (IV)
+ Acrylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]prop-2-enamide);
+
+
+ (V)
+ Parafluorofentanyl, also known as:
+
+ (aa)
+ 4-fluorofentanyl; or
+
+
+ (bb)
+ N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide;
+
+
+
+ (VI)
+ Butyryl fentanyl, also known as:
+
+ (aa)
+ Butyr fentanyl;
+
+
+ (bb)
+ NIH 10486; or
+
+
+ (cc)
+ N-phenyl-N-[l-(2-phenylethyl)-4-piperidinyl]-butanamide, monohydrochloride; and
+
+
+
+ (VII)
+ para-Fluorobutyryl fentanyl, also known as:
+
+ (aa)
+ 4-FPF;
+
+
+ (bb)
+ p-FBF;
+
+
+ (cc)
+ 4-Fluorobutyryl fentanyl;
+
+
+ (dd)
+ p-Fluorobutyryl fentanyl; or
+
+
+ (ee)
+ N-( 4-fluorophenyl)-N-[ l -(2-phenylethyl)-4-piperidinyl]-butanamide);
+
+
+
+
+ (ii)
+ Carbomethoxyfentanyls: Any compound containing or structurally derived from 4-((1-oxopropyl)-phenylamino )-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester, whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Carbomethoxyfentanyls include:
+
+ (I)
+ Carfentanil, also known as:
+
+ (aa)
+ 4-Carbomethoxy Fentanyl;
+
+
+ (bb)
+ 4-carbomethoxy Fentanyl; or
+
+
+ (cc)
+ 4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylic acid, methyl ester;
+
+
+
+ (II)
+ Norcarfentanil (also known as: 4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester; and
+
+
+ (III)
+ N-methyl Norcarfentanil, also known as:
+
+ (aa)
+ N-methyl Carfentanil;
+
+
+ (bb)
+ N-methyl Norremifentanil;
+
+
+ (cc)
+ N-methyl Remifentanil; or
+
+
+ (dd)
+ 1-methyl-4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester; and
+
+
+
+
+ (iii)
+ Benzamides: Any compound containing or structurally derived from 3,4-Dichloro-N-[(1 R,2R)-2-(dimethylamino )cyclohexyl]-N-methylbenzamide, whether or not substituted on the phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group, and whether or not substituted with an alkyl or hydrogen on the nitrogen of the amide, and whether or not substituted on the nitrogen of the amide with an alkyl, cycloalkyl, tertiary amine, or combination thereof. Benzamides include:
+
+ (I)
+ U-47700 (also known as 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide); and
+
+
+ (II)
+ AH-7921 (also known as 3,4-dichloro-N-{[l-(dimethylamino)cyclohexyl]methyl}benzamide).
+
+
+
+
+ (B)
+ Unclassified Synthetic Opioids:
+
+ (i)
+ W-18 (also known as 4-chloro-N-[(2Z)-l-[2-(4-nitrophenyl)ethyl]piperidin-2-ylidene ]benzene-I-sulfonamide);
+
+
+ (ii)
+ Sufentanil (also known as N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-propanamide);
+
+
+ (iii)
+ Alfentanil (also known as N-[1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-N-phenyl-propanamide);
+
+
+ (iv)
+ Remifentanil (also known as 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid, methyl ester);
+
+
+ (v)
+ Lofentanil (also known as methyl (3R,4S)-3-methyl-1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate);
+
+
+ (vi)
+ Benzyl Carfentanil (also known as methyl 1-benzyl-4-(N-phenylpropionamido)piperidine-4-carboxylate); and
+
+
+ (vii)
+ N-methyl-Norcarfentanil (also known as 1-methyl-4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester).
+
+
+
+
+ .
+
+
+
+
+
+ (c)
+ Section 208(a) (D.C. Official Code § 48-902.08(a)) is amended as follows:
+
+ (1)
+ Paragraph (5)(BB) is amended by striking the semicolon and inserting the phrase "; and" in its place.
+
+
+ (2)
+ Paragraph (6) is amended by striking the phrase "; and" and inserting a period.
+
+
+ (3)
+ Paragraph (7) is repealed.
+
+
+
+
+
+ 3
+ Fiscal impact statement.
+ The Council adopts the fiscal impact statement of the Chief Financial Officer as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).
+
+
+ 4
+ Effective date.
+ This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), and shall remain in effect for no longer than 90 days, as provided for emergency acts of the Council of the District of Columbia in section 412(a) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 788; D.C. Official Code § 1-204.12(a)).
+
+
diff --git a/dc/council/periods/22/acts/22-466.xml b/dc/council/periods/22/acts/22-466.xml
new file mode 100644
index 0000000000..c1d3d8e231
--- /dev/null
+++ b/dc/council/periods/22/acts/22-466.xml
@@ -0,0 +1,45 @@
+
+
+ 22-331
+ 22-466
+ Nonbinary Identification Cards Amendment Act of 2018
+ To amend the District of Columbia Traffic Act, 1925 to allow applicants for a license, permit, or identification card issued by the Department of Motor Vehicles to designate their gender as nonbinary.
+
+ 2017-06-20
+ 2018-12-15
+
+ D.C. Act 22-466
+ 65 DCR 11402
+
+
+
+
+ 2018-10-09
+ BILL SUMMARY - As introduced, this bill permits applicants for a District driver's license, learner's permit, or identification card to designate their gender as "nonbinary".
+ Committee on Transportation and the Environment
+
+
+ BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Nonbinary Identification Cards Amendment Act of 2018".
+
+ 2
+ Section 7 of the District of Columbia Traffic Act, 1925, approved March 3, 1925 (43 Stat. 1121; D.C. Official Code § 50-1401.01), is amended by adding a new subsection (i) to read as follows:
+
+
+
+ (i)
+ The Department shall allow applicants for a license, permit, or identification card issued pursuant to this section, section 8a, or section 8c to designate their gender as nonbinary.
+
+
+ .
+
+
+ 3
+ Fiscal impact statement.
+ The Council adopts the fiscal impact statement in the committee report as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).
+
+
+ 4
+ Effective date.
+ This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.
+
+
diff --git a/dc/council/periods/22/acts/22-467.xml b/dc/council/periods/22/acts/22-467.xml
new file mode 100644
index 0000000000..830decf044
--- /dev/null
+++ b/dc/council/periods/22/acts/22-467.xml
@@ -0,0 +1,251 @@
+
+
+ 22-500
+ 22-467
+ Specialty License Plate Omnibus Amendment Act of 2018
+ To amend the District of Columbia Revenue Act of 1937 to require the Mayor to design and issue motor vehicle identification tags with a separate design for each branch of the United States Armed Forces, to require the Mayor to issue a motor vehicle identification tag with a design, identifying words, or emblem that promotes breast cancer awareness, to require the Mayor to issue one or more parks and recreation motor vehicle identification tags to enhance the public's awareness of the District's diverse economic, health, and leisure programming at local parks and recreation centers, to require the Mayor to issue one or more Washington Capitals motor vehicle identification tags to demonstrate support for the Washington Capitals hockey team and celebrate the Washington Capitals Stanley Cup win in 2018, and to make conforming amendments.
+
+ 2017-10-03
+ 2018-12-15
+
+ D.C. Act 22-467
+ 65 DCR 11404
+
+
+
+
+ 2018-10-09
+ BILL SUMMARY - As introduced, this bill requires the Mayor to issue a motor vehicle identification tag promoting breast cancer awareness and establishes fee amounts for the identification tags. The bill specifies that the fees shall be deposited in the Community Health Care Financing Fund.
+ Committee on Transportation and the Environment
+
+
+ BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Specialty License Plate Omnibus Amendment Act of 2018".
+
+ 2
+ Title IV of the District of Columbia Revenue Act of 1937, approved August 17, 1937 (50 Stat. 679; D.C. Official Code § 50-1501.01 et seq.), is amended as follows
+
+ (a)
+ Section 2a(b) (D.C. Official Code § 50-1501.02a(b)), is amended as follows:
+
+ (1)
+ Paragraph (2) is amended by striking the phrase "one or more veterans' identification tags" and inserting the phrase "veterans' identification tags, which shall include separate designs for each branch of the United States Armed Forces" in its place.
+
+ one or more veterans' identification tags
+ veterans' identification tags, which shall include separate designs for each branch of the United States Armed Forces
+
+
+
+ (2)
+ Paragraph (3) is amended by striking the phrase "If more than one design of veterans' identification tag is available for issue, the" and inserting the word "The" in its place.
+
+ If more than one design of veterans' identification tag is available for issue, the
+ The
+
+
+
+
+ (b)
+ New sections 2f, 2g, and 2h are added to read as follows:
+
+
+
+ 2f
+ Issuance of breast cancer awareness motor vehicle identification tags.
+
+ (a)
+ The Mayor shall design and issue motor vehicle identification tags with a design, identifying words, or emblem that promotes breast cancer awareness.
+
+
+ (b)
+
+ (1)
+ A resident ordering a breast cancer awareness motor vehicle identification tag shall pay a one-time application fee and a display fee each year thereafter. The application fee shall be $25 and the display fee shall be $20, or other amounts as may be established by the Mayor by rule.
+
+
+ (2)
+ The application fee and annual display fee shall be deposited in the Community Health Care Financing Fund, established by section 101 of the Community Access to Health Care Amendment Act of 2006, effective March 14, 2007 (D.C. Law 16-288; D.C. Official Code § 7-1931).
+
+
+ Aug. 17, 1937, 50 Stat. 680, ch. 690, title IV, §2f
+
+
+
+ 2g
+ Issuance of parks and recreation motor vehicle identification tags.
+
+ (a)
+ The Mayor shall design and make available for issue one or more parks and recreation motor vehicle identification tags to enhance the public's awareness of the District's diverse economic, health, and leisure programming at local parks and recreation centers.
+
+
+ (b)
+
+ (1)
+ A resident ordering a parks and recreation motor vehicle identification tag shall pay a one-time application fee and a display fee each year thereafter. The application fee shall be $25 and the display fee shall be $20, or other amounts as may be established by the Mayor by rule.
+
+
+ (2)
+ The application fee and annual display fee shall be deposited in the Recreation Enterprise Fund, established by section 4 of the Recreation Act of 1994, effective March 23, 1995 (D.C. Law 10-246; D.C. Official Code § 10-303).
+
+
+ Aug. 17, 1937, 50 Stat. 680, ch. 690, title IV, §2g
+
+
+
+ 2h
+ Issuance of Washington Capitals motor vehicle identification tags.
+
+ (a)
+ The Mayor shall design and make available for issue one or more Washington Capitals motor vehicle identification tags to demonstrate support for the Washington Capitals hockey team and celebrate the Washington Capitals Stanley Cup win in 2018.
+
+
+ (b)
+
+ (1)
+ A resident ordering a Washington Capitals tag shall pay a one-time application fee and a display fee each year thereafter. The application fee shall be $25 and the display fee shall be $20, or other amounts as may be established by the Mayor by rule.
+
+
+ (2)
+ The application fee and annual display fee shall be deposited into the General Fund of the District of Columbia.
+
+
+ Aug. 17, 1937, 50 Stat. 680, ch. 690, title IV, §2g
+
+
+ .
+
+
+ (c)
+ Section 3 (D.C. Official Code § 50-1501.03) is amended as follows:
+
+ (1)
+ Subsection (a)(l) is amended by adding new subparagraphs (J), (K), and (L) to read as follows:
+
+
+
+ (J)
+ Any person ordering a breast cancer awareness identification tag shall pay the fees as set forth in section 2f(b)(1).
+
+
+
+ (K)
+ Any person ordering a parks and recreation identification tag shall pay the fees as set forth in section 2g(b)(1).
+
+
+
+ (L)
+ Any person ordering a Washington Capitals identification tag shall pay the fees as set forth in section 2h(b)(1).
+
+
+ .
+
+
+ (2)
+ Subsection (d) is amended as follows:
+
+ (A)
+ Paragraph (6) is amended by striking the phrase "; and" and inserting a semicolon in its place.
+
+ ; and
+ ;
+
+
+
+ (B)
+ Paragraph (7) is amended by striking the period and inserting a semicolon in its place.
+
+ .
+ ;
+
+
+
+ (C)
+ New paragraphs (8), (9), and (10) are added to read as follows:
+
+
+
+ (8)
+ The fees collected for breast cancer awareness identification tags under section 2f shall be deposited in the Community Health Care Financing Fund, established by section 101 of the Community Access to Health Care Amendment Act of 2006, effective March 14, 2007 (D.C. Law 16-288; D.C. Official Code § 7-1931);
+
+
+
+ (9)
+ The fees collected for parks and recreation identification tags under section 2g shall be deposited into the Recreation Enterprise Fund, established by section 4 of the Recreation Act of 1994, effective March 23, 1995 (D.C. Law 10-246; D.C. Official Code § 10-303); and
+
+
+
+ (10)
+ The fees collected for the Washington Capitals identification tags under section 2h shall be deposited into the General Fund of the District of Columbia.
+
+
+ .
+
+
+
+
+
+ 3
+ Section 101 of the Community Access to Health Care Amendment Act of 2006, effective March 14, 2007 (D.C. Law 16-288; D.C. Official Code § 7-1931), is amended as follows:
+
+ (a)
+ Subsection (a) is amended as follows:
+
+ (1)
+ Paragraph (3) is amended by striking the phrase "; and" and inserting a semicolon in its place.
+
+ ; and
+ ;
+
+
+
+ (2)
+ Paragraph (4) is amended by striking the period and inserting the phrase "; and" in its place.
+
+ .
+ ; and
+
+
+
+ (3)
+ A new paragraph (5) is added to read as follows:
+
+
+
+ (5)
+ Fees collected pursuant to section 2f(b)(1) of Title IV of the District of Columbia Revenue Act of 1937, passed on 2nd reading on September 18, 2018 (Enrolled version of Bill 22-500).
+
+
+ .
+
+
+
+ (b)
+ Subsection (b) is amended by striking the phrase "programs, or" and inserting the phrase "programs, promoting breast cancer prevention and treatment, or" in its place.
+
+ programs, or
+ programs, promoting breast cancer prevention and treatment, or
+
+
+
+
+ 4
+ Section 4 of the Recreation Act of 1994, effective March 23, 1995 (D.C. Law 10-246; D.C. Official Code § 10-303), is amended by adding a new subsection (f) to read as follows:
+
+
+
+ (f)
+ All fees collected pursuant to section 2g(b)(1) of Title IV of the District of Columbia Revenue Act of 1937, passed on 2nd reading on September 18, 2018 (Enrolled version of Bill 22-500), shall be deposited into the Fund.
+
+
+ .
+
+
+ 5
+ Fiscal impact statement.
+ The Council adopts the fiscal impact statement in the committee report as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).
+
+
+ 6
+ Effective date.
+ This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.
+
+
diff --git a/dc/council/periods/22/acts/22-468.xml b/dc/council/periods/22/acts/22-468.xml
new file mode 100644
index 0000000000..d48aa8f429
--- /dev/null
+++ b/dc/council/periods/22/acts/22-468.xml
@@ -0,0 +1,110 @@
+
+
+ 22-681
+ 22-468
+ Healthy Parks Amendment Act of 2018
+ To amend the Recreation Act of 1994 to update nutritional standards for food and beverages provided, offered, or sold at parks and recreation facilities, to require the Department of Parks and Recreation to offer reimbursable suppers on each weekday to children present at a Department of Parks and Recreation facility through the Afterschool Meals Program, to require the Department of Parks and Recreation to publish and implement a written annual plan to expand participation in the Summer Food Service Program and the Afterschool Meals Program, and to require the Department of Parks and Recreation to coordinate with relevant community groups, Advisory Neighborhood Commissions, and the Council in order to develop and implement the written annual plans.
+
+ 2018-02-06
+ 2018-12-15
+
+ D.C. Act 22-468
+ 65 DCR 11408
+
+
+
+
+ 2018-10-09
+ BILL SUMMARY - As introduced, this bill requires that all food and beverages distributed by the Department of Parks and Recreation (DPR) or their agents must meet the requirements of the District school meal standards or the federal competitive food service standards at the high school level. It requires DPR to offer youth attending afterschool enrichment programs a supper meal through participation in the Child and Adult Care Food Program's At-Risk Afterschool Meals Program. Among other things DPR must also expand its participation in the Summer Food Service Program.
+ Committee on Transportation and the Environment
+
+
+ BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Healthy Parks Amendment Act of 2018".
+
+ 2
+ Section 3b of the Recreation Act of 1994, effective April 23, 2013 (D.C. Law 19-280; D.C. Official Code § 10-302.02), is amended as follows:
+
+ (a)
+ Subsection (a) is amended to read as follows:
+
+
+
+ (a)
+ Except as provided in subsection (b) of this section, all food and beverages sold, offered, or provided by the Department or its agents on buildings, grounds, or other facilities under the Department's jurisdiction, control, or use shall meet the following requirements:
+
+ (1)
+ For meals, as that term is defined in section 101(5) of the Healthy Schools Act of 2010, effective July 27, 2010 (D.C. Law 18-209; D.C. Official Code § 38-821.01(5)) ("Healthy Schools Act"), the standards set forth in section 202 of the Healthy Schools Act; and
+
+
+ (2)
+ For food and beverages other than meals, as that term is defined in section 101(5) of the Healthy Schools Act, including snacks and food and beverages sold through vending machines and concessions, the nutrition standards for competitive food applicable to high school-aged students, as described in 7 C.F.R. § 210.11.
+
+
+
+ .
+
+
+ (b)
+ Subsection (c) is amended by adding new paragraphs (3) and (4) to read as follows:
+
+
+
+ (3)
+ The Department shall offer reimbursable suppers on each weekday to children present at a Department facility through the Afterschool Meals Program, as provided in 7 C.F.R. § 226.17a.
+
+
+
+ (4)
+
+ (A)
+ By February 1 of each year, the Department shall publish a written plan to increase participation in the Summer Food Service Program and the Afterschool Meals Program.
+
+
+ (B)
+ In order to develop and implement the plan required by subparagraph (A) of this paragraph, the Department shall coordinate with relevant community groups, Advisory Neighborhood Commissions, and the Council.
+
+
+
+ .
+
+
+
+
+ 3
+ Applicability.
+
+ (a)
+ The amendatory section 3b(c)(3) within section 2(b) shall apply upon the date of inclusion of its fiscal effect in an approved budget and financial plan.
+
+
+ Repealed
+ Not Funded
+
+
+
+ (b)
+ The Chief Financial Officer shall certify the date of the inclusion of the fiscal effect in an approved budget and financial plan, and provide notice to the Budget Director of the Council for certification.
+
+
+ (c)
+
+ (1)
+ The Budget Director shall cause the notice of the certification to be published in the District of Columbia Register.
+
+
+ (2)
+ The date of publication of the notice of the certification shall not affect the applicability of the amendatory section 3b(c)(3) within section 2(b).
+
+
+
+
+ 4
+ Fiscal impact statement.
+ The Council adopts the fiscal impact statement in the committee report as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).
+
+
+ 5
+ Effective date.
+ This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.
+
+
diff --git a/dc/council/periods/22/acts/22-469.xml b/dc/council/periods/22/acts/22-469.xml
new file mode 100644
index 0000000000..8bf4d6612b
--- /dev/null
+++ b/dc/council/periods/22/acts/22-469.xml
@@ -0,0 +1,65 @@
+
+
+ 22-894
+ 22-469
+ Office of Public-Private Partnerships Delegation of Authority Temporary Amendment Act of 2018
+ To amend, on a temporary basis, the Procurement Practices Reform Act of 2010 and the Public-Private Partnership Act of 2014 to allow the Office of Public-Private Partnerships to delegate its contracting authority for public-private partnership agreements to the Office of Contracting and Procurement, and to require any employee of the Office of Contracting and Procurement exercising such delegated authority to comply with provisions of the Public-Private Partnership Act of 2014 and any regulations promulgated to effectuate it.
+
+ 2018-07-10
+ 2018-12-15
+
+
+ D.C. Act 22-469
+ 65 DCR 11410
+
+
+
+
+ 2018-10-10
+
+ Retained by the Council
+
+
+ BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Office of Public-Private Partnerships Delegation of Authority Temporary Amendment Act of 2018".
+
+ 2
+ Section 201(f) of the Procurement Practices Reform Act of 2010, effective April 8, 2011 (D.C. Law 18-371; D.C. Official Code § 2-352.01(f)), is amended by striking the phrase "requirements of this act" and inserting the phrase "requirements of this act, except as provided in section 102(e) of the Public-Private Partnership Act of 2014, effective March 11, 2015 (D.C. Law 20-228; D.C. Official Code § 2-272.01(e))" in its place.
+
+
+
+ 3
+ Section 102 of the Public-Private Partnership Act of 2014, effective March 11, 2015 (D.C. Law 20-228; D.C. Official Code § 2-272.01), is amended by adding a new subsection (e) to read as follows:
+
+
+ (e)
+
+ (1)
+ The Office may delegate to the Office of Contracting and Procurement ("OCP"), at the discretion of OCP, the authority to serve as the contracting officer for the Office for public-private partnership agreements entered into pursuant to this act and to carry out other contracting functions related to public-private partnerships on behalf of the Office.
+
+
+ (2)
+ Any OCP employee exercising authority delegated pursuant to this subsection shall comply with the provisions of this act and any rules and regulations promulgated to effectuate this act.
+
+
+
+ .
+
+
+
+ 4
+ Fiscal impact statement.
+ The Council adopts the fiscal impact statement of the Budget Director as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).
+
+
+ 5
+ Effective date.
+
+ (a)
+ This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.
+
+
+ (b)
+ This act shall expire after 225 days of its having taken effect.
+
+
+
diff --git a/dc/council/periods/22/acts/22-470.xml b/dc/council/periods/22/acts/22-470.xml
new file mode 100644
index 0000000000..04e7717034
--- /dev/null
+++ b/dc/council/periods/22/acts/22-470.xml
@@ -0,0 +1,65 @@
+
+
+ 22-898
+ 22-470
+ D.C. General Resident Relocation Temporary Act of 2018
+ To require, on a temporary basis, that demolition at the current D.C. General Family Shelter site meet all applicable environmental, health, and safety standards and that current D.C. General Family Shelter residents be relocated into safe, appropriate housing.
+
+ 2018-07-10
+ 2018-12-15
+
+
+ D.C. Act 22-470
+ 65 DCR 11412
+
+
+
+
+ 2018-10-10
+
+ Retained by the Council
+
+
+ BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "D.C. General Resident Relocation Temporary Act of 2018".
+
+ 2
+
+ (a)
+ The abatement, deconstruction, or demolition of any existing structure at the D.C. General Family Shelter site shall meet all applicable environmental, health, and safety standards.
+
+
+ (b)
+ Beginning on July 27, 2018 and weekly thereafter until there are no shelter residents remaining at the D.C. General Family Shelter, the Mayor shall report to the Council the number of samples taken at the D.C. General Family Shelter site for lead or asbestos testing and whether any of those samples exceeds permissible Environmental Protection Agency and Occupational Safety and Health Administration exposure limits for lead or asbestos.
+
+
+ (c)
+
+ (1)
+ Relocation of shelter residents from the D.C. General Family Shelter shall be to appropriate permanent housing as defined by section 2(4) of the Homeless Services Reform Act of 2005, effective October 22, 2005 (D.C. Law 16-35; D.C. Official Code § 4-751.01(4)), to the facilities constructed to provide temporary shelter pursuant to the Homeless Shelter Replacement Act of 2016, effective July 29, 2016 (D.C. Law 21-141; 63 DCR 8453), or to any units under contract by the District specifically for the purpose of housing D.C. General Family Shelter residents.
+
+
+ (2)
+ The Mayor shall provide a report to the Council, beginning on July 27, 2018 and weekly thereafter, indicating the current number of families continuing to reside at the D.C. General Family Shelter, the number of exits detailed by program, and the number of families confronting significant barriers to lease-up.
+
+
+ (3)
+ Upon closure of the D.C. General Family Shelter, the Mayor shall provide a report to the Council indicating the number of families that remained at closure that necessitated a swift exit and the status of those families.
+
+
+
+
+
+ 3
+ Fiscal impact statement.
+ The Council adopts the fiscal impact statement of the Budget Director as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).
+
+
+ 4
+ Effective date.
+ This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.
+
+ (b)
+ This act shall expire after 225 days of its having taken effect.
+
+
+
diff --git a/dc/council/periods/22/index.xml b/dc/council/periods/22/index.xml
index 0b51e558be..cb85e8f26d 100644
--- a/dc/council/periods/22/index.xml
+++ b/dc/council/periods/22/index.xml
@@ -110,6 +110,9 @@
Acts pending congressional review
+
+
+
@@ -127,6 +130,7 @@
Emergency Acts
+
@@ -291,6 +295,9 @@
Acts pending congressional review
+
+
+